Choosing AR-Targeted Therapy in CSPC

Treating mCSPC with Anti-Androgen Therapy and Monitoring for Progression

During a live virtual event, Roby A. Thomas, MD, discussed the tolerability of androgen receptor therapy and personal experiences with treatment of patients with metastatic castration-sensitive prostate cancer. This is the second of 2 articles based on this event.

Counseling Patients on Systemic Therapy for Metastatic CSPC

During a live virtual event, Roby A. Thomas, MD, discussed the choice of therapy for a patient with metastatic castration-sensitive prostate cancer.

Part 2: Updated Results Show Long-Term Survival Benefit for Apalutamide in mCSPC

During a live virtual event, Matthew B. Rettig, MD, discussed the results of the TITAN trial of apalutamide for patients with metastatic castration-sensitive prostate cancer.

Part 1: Reviewing the Systemic Therapy Options for Metastatic CSPC

During a live virtual event, Matthew B. Rettig, MD, discussed the guidelines and practical considerations for giving the 4 approved agents for metastatic castration-sensitive prostate cancer.

Monitoring Responses to Novel Hormonal Agents in Metastatic CSPC

During a live virtual event, Daniel C. Danila, MD, discussed how to treat a patient with de novo metastatic castration-sensitive prostate cancer and monitor for disease progression.

TITAN Trial Finds Survival Benefit for Apalutamide in mCSPC

Daniel P. Petrylak, MD, discusses the design and results of the TITAN trial of apalutamide in patients with metastatic castration-sensitive prostate cancer.

The Impact of Apalutamide Approval on the CSPC Landscape

Daniel P. Petrylak, MD, discusses the impact of the approval of apalutamide in the metastatic castration-sensitive prostate cancer setting.